The APIS BC Subtyping Kit represents a promising advancement towards standardized, precise, and reliable assessment of ER, PR, HER2, and Ki67 expression, holding the potential to improve breast cancer diagnostic pathways. This evidence concerns the gene ESR1 and breast cancer.